Expert Interview
A third look: Discussing the potential of Zilebesiran, an inhibitor of hepatic angiotensinogen synthesis, in development by Alnylam Pharmaceuticals as an injection for patients with hypertension.
Ticker(s): ALNYInstitution: BJC Medical Group
- Board-Certified in Interventional Cardiology and Cardiovascular Disease
- interested in renal denervation and hopes to perform the procedure in the future once it’s FDA approved
- treats many patients with resistant hypertension and is familiar with the Spyral RDN system
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
